Innovent Biologics' Sintilimab ZYBRIVO® Receives Positive CHMP Opinion, Recommended for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer

Stock News11-16 07:54

Innovent Biologics (01801) has announced that sintilimab (European trade name: Zybrivo®) has received its first positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). The CHMP has recommended the approval of sintilimab in combination with chemotherapy for the marketing authorization of adult patients with advanced non-squamous non-small cell lung cancer (NSCLC).

If approved by the European Commission, Zybrivo will expand first-line treatment options for lung cancer patients in Europe. Sintilimab is an immunotherapy drug, a fully human immunoglobulin G4 (IgG4) monoclonal antibody that binds to programmed cell death protein 1 (PD-1).

The CHMP's recommendation is based on results from the Phase III ORIENT-11 study (NCT03607539). This study was a randomized, multicenter, double-blind, placebo-controlled Phase III trial that enrolled 397 adult patients with locally advanced, metastatic, or recurrent non-squamous NSCLC, without EGFR or ALK genomic tumor aberrations, regardless of PD-L1 expression level.

Patients were randomized 2:1 to receive sintilimab or placebo, both in combination with pemetrexed and platinum-based chemotherapy. The primary endpoint was progression-free survival (PFS) as assessed by a blinded independent radiological review committee.

In the ORIENT-11 study, compared with placebo plus chemotherapy, sintilimab plus chemotherapy reduced the risk of disease progression or death by 52% (median PFS: 8.9 months vs. 5.0 months) and reduced the risk of death by 35% (median overall survival (OS): 24.2 months vs. 16.8 months). The study results demonstrated the clinical benefit of sintilimab plus chemotherapy and its potential to provide an additional first-line treatment option for eligible European patients with advanced non-squamous NSCLC.

The safety profile of sintilimab plus chemotherapy was consistent with the known safety profiles of PD-1 inhibitors and the chemotherapy agents used, with no new safety signals identified.

The indication recommended for approval by the CHMP this time is: Zybrivo in combination with pemetrexed and platinum-based chemotherapy, for the first-line treatment of adult patients with non-squamous NSCLC without epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations, and who meet the following conditions: locally advanced NSCLC and are not candidates for curative surgery or chemoradiation; or metastatic NSCLC.

The company's mission is to develop high-quality biologics that are affordable for the general public. The positive CHMP opinion for sintilimab is an important regulatory milestone in the company's international development process and brings the company one step closer to serving patients in Europe. The ORIENT-11 study confirmed the clear clinical benefit of sintilimab, and if approved, this drug will add a new treatment option for European patients with non-squamous non-small cell lung cancer.

At the same time, the company is strengthening its capabilities to support patient access to the product in major European markets. The company will continue to advance the development of innovative therapies and strive to bring more valuable therapeutic drugs to patients worldwide. Following the positive CHMP opinion, the European Commission is expected to make a final decision on the marketing authorization in the coming months. If approved, the authorization will be valid in all 27 EU member states, as well as Iceland, Norway, and Liechtenstein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment